Physician profile
Amanda E Hinkle
NPI 1255658290
$2,611.39
in general payments reported to CMS, 2019-2025
28 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $440 · 2023: $544 · 2024: $527 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.73 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.73 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.14 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $203.04 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Novo Nordisk INC | $181.00 | 2021-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $141.24 | 2021-2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $124.27 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $111.30 | 2021 | |
| Lilly USA, LLC | $110.72 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $79.64 | 2021-2023 | Dexcom G6 Transmitter |
| Alkermes, INC. | $79.36 | 2024-2025 | Vivitrol |
| Glaxosmithkline, LLC. | $63.46 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $60.39 | 2023-2024 | Rexulti, Abilify Maintena |
| Indivior INC. | $57.54 | 2024-2025 | Sublocade |
| Braeburn INC. | $57.31 | 2024-2025 | Brixadi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.69 | 2021 | |
| Lundbeck LLC | $38.11 | 2023-2024 | Rexulti |
| Averitas Pharma INC. | $33.59 | 2024 | Qutenza |
| Ironshore Pharmaceuticals INC. | $31.50 | 2023 | Jornay Pm |
| Amgen INC. | $29.72 | 2021-2022 | |
| Pfizer INC. | $29.57 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.74 | 2023 | Keveyis |
| Amarin Pharma, INC. | $21.75 | 2021 | |
| Verona Pharma, INC. | $20.03 | 2025 | Ohtuvayre |
| Evoke Pharma, INC. | $15.80 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.86 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.